Fortress Biotech (FBIO) Current Deferred Revenue (2016 - 2023)

Fortress Biotech's Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $547000.0 for Q1 2023.

• In Q1 2023, Current Deferred Revenue fell 73.11% year-over-year to $547000.0; the TTM figure through Mar 2023 stood at $547000.0 (down 73.11% YoY), while the FY2022 annual figure was $728000.0, down 72.12% from the prior year.
• Current Deferred Revenue for Q1 2023 stood at $547000.0, down from $728000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $7.2 million in Q1 2021, with the low at $547000.0 in Q1 2023.
• The 3-year median for Current Deferred Revenue is $2.0 million (2022), against an average of $2.6 million.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue plunged 67.41% in 2022, then slumped 73.11% in 2023.
• Fortress Biotech's Current Deferred Revenue stood at $2.6 million in 2021, then plunged by 72.12% to $728000.0 in 2022, then fell by 24.86% to $547000.0 in 2023.
• Business Quant data shows FBIO's Current Deferred Revenue at $547000.0 in Q1 2023, $728000.0 in Q4 2022, and $1.1 million in Q3 2022.